Highnoon Laboratories Ltd
Public listed pharmaceutical manufacturer · Lahore · Pakistan
Publicly listed Lahore pharmaceutical manufacturer with a broad therapeutic portfolio, research and development operations and national distribution.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Highnoon Laboratories Limited
- Company type
- Public listed pharmaceutical manufacturer
- Address
- 17.5 KM, Multan Road, Lahore 53700, Pakistan · 53700
- Website
- highnoon-labs.com ↗
- Phone
- +92 42 111 000 465
- info@highnoon.com.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Combivair | Budesonide + Formoterol | 6 mcg + 400 mcg | Inhalation capsule | 40's | 054317 | PKR 889.96 | PKR 22.25/capsule | Near median |
| Combivair Forte | Budesonide + Formoterol | 400 mcg + 12 mcg | Inhalation capsule | 30 | 107193 | PKR 690.31 | PKR 23.01/capsule | 24% below median |
| Combivair Forte | Budesonide + Formoterol | 400 mcg + 12 mcg | Inhalation capsule | 60 | 107193 | PKR 1,353.00 | PKR 22.55/capsule | 26% below median |
| Combivair Forte | Budesonide | 400 mcg | Inhalation capsule | 40 | 107193 | PKR 902.01 | PKR 22.55/capsule | 86% above median |
| Combivair Forte | Budesonide | 400 mcg | Inhalation capsule | 50 | 107193 | PKR 1,127.51 | PKR 22.55/capsule | 86% above median |
| Cyrocin | Ciprofloxacin | 250 mg | Tablet | 10 | 011406 | PKR 364.67 | PKR 36.47/tablet | 44% above median |
| Cyrocin | Ciprofloxacin | 500 mg | Tablet | 10 | 011407 | PKR 679.78 | PKR 67.98/tablet | 59% above median |
| Cyrocin | Ciprofloxacin | 750 mg | Tablet | 10 | 038499 | PKR 458.54 | PKR 45.85/tablet | 16% above median |
| Cyrocin | Ciprofloxacin | 250 mg/5 mL | Suspension | 60 ml | 071579 | PKR 330.46 | PKR 5.51/mL | 7% above median |
| Cyrocin | Ciprofloxacin | 125 mg/5 mL | Suspension | 60 ml | 071580 | PKR 222.36 | PKR 3.71/mL | Near median |
| Cytarabine Injection | Cytarabine | 100 mg | Injection | 1 | 016169 | PKR 349.99 | — | No comparator |
| Daclata | Daclatasvir | 30 mg | Tablet | 28 | 089434 | PKR 5,223.91 | PKR 186.57/tablet | Near median |
| Daclata | Daclatasvir | 60 mg | Tablet | 28 | 089435 | PKR 9,530.12 | PKR 340.36/tablet | Near median |
| Defal | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6 | 067821 | PKR 682.48 | PKR 113.75/tablet | Near median |
| Diajard | Empagliflozin | 10 mg | Tablet | 20 | 106568 | PKR 1,473.62 | PKR 73.68/tablet | 11% below median |
| Diajard | Empagliflozin | 10 mg | Tablet | 14 | 106568 | PKR 1,052.59 | PKR 75.19/tablet | 9% below median |
| Diajard | Empagliflozin | 25 mg | Tablet | 20 | 106582 | PKR 1,763.81 | PKR 88.19/tablet | 12% below median |
| Diajard | Empagliflozin | 25 mg | Tablet | 14 | 106582 | PKR 1,259.87 | PKR 89.99/tablet | 10% below median |
| Diuvir 200/ Lopinavir + RitonavirSource observed | — | 50 mg | Tablet | 120 | 109293Official source ↗ | No indexed price | — | — |
| Diuvir 200/50 mg Tablet Lopinavir 200 mg + Ritonavir 20 mgSource observed | — | — | — | 120 | 109293Official source ↗ | No indexed price | — | — |
| Dongsulin 70/30Source observed | Human insulin premix 30/70 (30% regular + 70% NPH) | 100 IU/mL | Injection | 10 ml | 039880Official source ↗ | No indexed price | — | — |
| Dongsulin 70/30Source observed | Human insulin premix 30/70 (30% regular + 70% NPH) | 300 IU/3 mL | Suspension for injection | 3 ml Catridge | 041121Official source ↗ | No indexed price | — | — |
| Dongsulin 70/30 10 ml vial Recombinant Human Insulin 1000 IUSource observed | — | — | — | 10 ml | 039880Official source ↗ | No indexed price | — | — |
| Dongsulin N | Human insulin (isophane/NPH) | 100 IU/mL (1000 IU/10 mL) | Suspension for injection | 1 | 039881 | PKR 1,030.44 | — | No comparator |
| Dongsulin N | Human insulin (isophane/NPH) | 1000 IU | Injection | 1 | 039881 | PKR 1,030.44 | — | No comparator |
| Dongsulin N | Human insulin (isophane/NPH) | 300 IU/3 mL | Suspension for injection | 3 ml Catridge | 041122 | PKR 351.77 | PKR 117.26/mL | No comparator |
| Dongsulin R | Regular human insulin | 100 IU/mL (1000 IU/10 mL) | Solution for injection | 1 | 039879 | PKR 1,030.44 | — | No comparator |
| Dongsulin R | Human insulin (isophane/NPH) | 1000 IU | Injection | 1 | 039879 | PKR 1,030.44 | — | No comparator |
| Dongsulin R | Regular human insulin | 300 IU/3 mL | Solution for injection | 3 ml Catridge | 041120 | PKR 351.77 | PKR 117.26/mL | No comparator |
| Efix | Cefixime | 400 mg | Capsule | 5 | 059519 | PKR 548.67 | PKR 109.73/capsule | Near median |
| Efix dry | Cefixime | 100 mg/5 mL | Dry suspension | 30ML | 059520 | PKR 330.39 | PKR 11.01/mL | 5% above median |
| Efix DS Dry | Cefixime | 200 mg/5 mL | Dry suspension | 30 ML | 084825 | PKR 404.31 | PKR 13.48/mL | Near median |
| Emesson | Ondansetron | 4 mg | Tablet | 10 | 110632 | PKR 767.30 | PKR 76.73/tablet | 17% below median |
| Emesson | Ondansetron | 4 mg/5 mL | Oral solution | 50ml | 110633 | PKR 743.51 | PKR 14.87/mL | 28% below median |
| Emesson | Ondansetron | 8 mg | Tablet | 10 | 110634 | PKR 1,278.84 | PKR 127.88/tablet | 23% below median |
| Emesson | Ondansetron | 8 mg | Injection | 5 | 110635 | PKR 3,843.95 | — | No comparator |
| Emesson | Ondansetron | 8 mg | Injection | 1 | 110635 | PKR 768.79 | — | No comparator |
| Emesson | Ondansetron | 4 mg | Injection | 5 | 110994 | PKR 2,538.84 | — | No comparator |
| Emesson | Ondansetron | 4 mg | Injection | 1 | 110994 | PKR 572.50 | — | No comparator |
| Envir | Entecavir | 1 mg | Tablet | 30 | 069040 | PKR 42,161.44 | PKR 1,405.38/tablet | 143% above median |
| Envir | Entecavir | 0.5 mg | Tablet | 30 | 069041 | PKR 21,760.74 | PKR 725.36/tablet | 104% above median |
| Foracort 100 | Budesonide + Formoterol | 100 mcg + 6 mcg | HFA inhaler | 1 | 072586 | PKR 1,075.28 | — | No comparator |
| Foracort 200 | Budesonide + Formoterol | 200 mcg + 6 mcg | HFA inhaler | 1 | 072587 | PKR 1,259.13 | — | No comparator |
| Fosbu | Sofosbuvir | 400 mg | Tablet | 28 | 085160 | PKR 11,705.11 | PKR 418.04/tablet | Near median |
| Fosbu | Sofosbuvir + Velpatasvir | 400 mg + 100 mg | Tablet | 14 | 099827 | PKR 7,557.78 | PKR 539.84/tablet | 23% below median |
| Fosbu V | Sofosbuvir + Velpatasvir | 400 mg + 100 mg | Tablet | 28 | 099827 | PKR 16,057.26 | PKR 573.47/tablet | 18% below median |
| Fosbu V 400 | Sofosbuvir + Velpatasvir | 100 mg + 100 mg | Tablet | 14 | 099827 | PKR 7,557.78 | PKR 539.84/tablet | No comparator |
| Hi-Multivit | Vitamin A + Vitamin D + Thiamine + Riboflavin + Nicotinamide + Vitamin C | 2500 IU + 300 IU + 1 mg + 0.5 mg + 7.5 mg + 15 mg | Tablet | 100 | 006360 | PKR 824.52 | PKR 8.25/tablet | No comparator |
| Hi-Multivit | Vitamin A | 2500 IU | Tablet | 1000's | 006360 | PKR 38.59 | PKR 0.04/tablet | No comparator |
| Hi-Zync DRY powder (lpSource observed | Zinc (elemental) | 100 mg + 3.64 mg | Suspension | 30 ML | 071577Official source ↗ | No indexed price | — | — |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.